The University of North Carolina-Chapel HIll (UNC) Clinical Center leads the eight Drug-Induced Liver Injury Network (DILIN) centers in terms of total subject recruitment and number of ancillary studies proposed and conducted. Dr. Paul Watkins has served as chair of the Steering Committee since 2003, when the network was created. Dr. Herbert Bonkovsky was PI at University of Connecticut, one of the original DILIN clinical sites, and since joining the UNC Clinical Center, he has continued to be very active in subject recruitment, ancillary study execution, and general guidance for the network. Dr. Paul Hayashi serves as co-chair of the network's Causality Assessment Committee. In addition to continuing in these administrative roles, we proposed to enroll at least 75 percent of DILIN subjects within 15 days of the initial health care encounter and to continue to lead the network in total subject recruitment (Specific Aim 1). We will work with DILIN investigators to further develop the LiverTox website and to create within it a new DILI diagnostic instrument that is accurate, simple, and practical for clinicians (Specific Aim 2). Finally, we propose conducting DILIN ancillary studies by utilizing fully the research infrastructure and international collaborations we have built specifically for this purpose (Specific Aim 3). With this funding, we believe the UNC Clinical Center would be well positioned to capitalize on the unprecedented resources we would help to develop within DILIN to achieve a level of mechanistic understanding that could revolutionize the diagnosis and management of DILI.
Drug-induced liver injury remains the major adverse event that results in regulatory actions that prevent important new drugs from helping patients. The data and tissue banks created by the DILIN network provide the needed resources to solve this important public health problem.
|Hayashi, Paul H; Barnhart, Huiman X; Fontana, Robert J et al. (2015) Reliability of causality assessment for drug, herbal and dietary supplement hepatotoxicity in the Drug-Induced Liver Injury Network (DILIN). Liver Int 35:1623-32|
|Kleiner, David E; Chalasani, Naga P; Lee, William M et al. (2014) Hepatic histological findings in suspected drug-induced liver injury: systematic evaluation and clinical associations. Hepatology 59:661-70|
|Fontana, Robert J; Hayashi, Paul H; Gu, Jiezhun et al. (2014) Idiosyncratic drug-induced liver injury is associated with substantial morbidity and mortality within 6 months from onset. Gastroenterology 147:96-108.e4|
|Russo, Mark W; Hoofnagle, Jay H; Gu, Jiezhun et al. (2014) Spectrum of statin hepatotoxicity: experience of the drug-induced liver injury network. Hepatology 60:679-86|
|Bonacini, Maurizio; Ghabril, Marwan; Bonkovsky, Herbert L (2014) Hepatotoxicity of anti-TNF agents. Dig Dis Sci 59:1070-1|
|Ghaziani, Tahereh; Sendi, Hossein; Shahraz, Saeid et al. (2014) Hepatitis B and liver transplantation: molecular and clinical features that influence recurrence and outcome. World J Gastroenterol 20:14142-55|
|deLemos, Andrew S; Foureau, David M; Jacobs, Carl et al. (2014) Drug-induced liver injury with autoimmune features. Semin Liver Dis 34:194-204|
|Ghabril, Marwan; Bonkovsky, Herbert L; Kum, Clarissa et al. (2013) Liver injury from tumor necrosis factor-* antagonists: analysis of thirty-four cases. Clin Gastroenterol Hepatol 11:558-564.e3|
|Urban, Thomas J (2013) Whole-genome sequencing in pharmacogenetics. Pharmacogenomics 14:345-8|
|Maddukuri, Vinaya C; Russo, Mark W; Ahrens, William A et al. (2013) Chronic hepatitis E with neurologic manifestations and rapid progression of liver fibrosis in a liver transplant recipient. Dig Dis Sci 58:2413-6|
Showing the most recent 10 out of 29 publications